NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma

被引：0

作者：

Vilde Drageset Haakensen

Anna K. Nowak

Espen Basmo Ellingsen

Saima Jamil Farooqi

Maria Moksnes Bjaanæs

Henrik Horndalsveen

Tine Mcculloch

Oscar Grundberg

Susana M. Cedres

Åslaug Helland

机构：

[1] Oslo University Hospital,Department of Oncology

[2] Oslo University Hospital,Department of Cancer Genetics, Institute for Cancer Research

[3] University of Western Australia,National Centre for Asbestos Related Diseases, Institute for Respiratory Health

[4] Sir Charles Gairdner Hospital,Department of Medical Oncology

[5] Oslo University Hospital,Department of Tumor Biology, Institute for Cancer Research

[6] Ultimovacs,Department of Oncology and Clinical Cancer Research Center

[7] Aalborg University Hospital,Department of Clinical Medicine, Faculty of Medicine

[8] Aalborg University,Thoracic Oncology Center, Theme Cancer

[9] Karolinska University Hospital,Oncology Department

[10] Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology,Faculty of Medicine

[11] University of Oslo,undefined

来源：

Journal of Translational Medicine | / 19卷

关键词：

Malignant pleural mesothelioma; Telomerase vaccine; Immunotherapy; hTERT; Nivolumab; Ipilimumab; Biomarker; Immune response;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[21] PEMbrolizumab Plus Lenvatinib In Second And Third Line Malignant Pleural MEsotheLiomA Patients: A Single Arm Phase II Study (PEMMELA)
Douma, L. -A. H.
de Gooijer, C. J.
Noort, V. v. D.
Lalezari, F.
de Vries, J. F.
Vermeulen, M.
Schilder, B.
Smesseim, I.
Baas, P.
Burgers, J. A.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S13 - S13
[22] EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study
Zauderer, Marjorie G.
Szlosarek, Peter W.
Le Moulec, Sylvestre
Popat, Sanjay
Taylor, Paul
Planchard, David
Scherpereel, Arnaud
Koczywas, Marianna
Forster, Martin
Cameron, Robert B.
Peikert, Tobias
Michaud, Neil R.
Szanto, Attila
Yang, Jay
Chen, Yingxue
Kansra, Vikram
Agarwal, Shefali
Fennell, Dean A.
LANCET ONCOLOGY, 2022, 23 (06) : 758 - 767
[23] Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma
Lisa Zimmer
Thomas K. Eigentler
Felix Kiecker
Jan Simon
Jochen Utikal
Peter Mohr
Carola Berking
Eckhart Kämpgen
Edgar Dippel
Rudolf Stadler
Axel Hauschild
Michael Fluck
Patrick Terheyden
Rainer Rompel
Carmen Loquai
Zeinab Assi
Claus Garbe
Dirk Schadendorf
Journal of Translational Medicine, 13
[24] Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study
Ueno, Makoto
Ikeda, Masafumi
Morizane, Chigusa
Kobayashi, Satoshi
Ohno, Izumi
Kondo, Shunsuke
Okano, Naohiro
Kimura, Keisuke
Asada, Suguru
Namba, Yoshinobu
Okusaka, Takuji
Furuse, Junji
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2019, 4 (08): : 611 - 621
[25] First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial
Paz-Ares, Luis G.
Ramalingam, Suresh S.
Ciuleanu, Tudor-Eliade
Lee, Jong-Seok
Urban, Laszlo
Caro, Reyes Bernabe
Park, Keunchil
Sakai, Hiroshi
Ohe, Yuichiro
Nishio, Makoto
Audigier-Valette, Clarisse
Burgers, Jacobus A.
Pluzanski, Adam
Sangha, Randeep
Gallardo, Carlos
Takeda, Masayuki
Linardou, Helena
Lupinacci, Lorena
Lee, Ki Hyeong
Caserta, Claudia
Provencio, Mariano
Carcereny, Enric
Otterson, Gregory A.
Schenker, Michael
Zurawski, Bogdan
Alexandru, Aurelia
Vergnenegre, Alain
Raimbourg, Judith
Feeney, Kynan
Kim, Sang-We
Borghaei, Hossein
O'Byrne, Kenneth John
Hellmann, Matthew D.
Memaj, Arteid
Nathan, Faith Ellen
Bushong, Judith
Phuong Tran
Brahmer, Julie R.
Reck, Martin
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (02) : 289 - 308
[26] Multisite Radiotherapy Combined With Tislelizumab for Metastatic Castration-Resistant Prostate Cancer With Second-Line and Above Therapy Failure: Study Protocol for an Open-Label, Single-Arm, Phase Ib/II Study
Cheng, Ke
Wang, Yuqing
Chen, Ye
Zhu, Jingjie
Qi, Xiaohui
Wang, Yachen
Zou, Yanqiu
Lu, Qiuhan
Li, Zhiping
FRONTIERS IN ONCOLOGY, 2022, 12
[27] PD-1 Inhibitor Combined With Radiotherapy and GM-CSF (PRaG) in Patients With Metastatic Solid Tumors: An Open-Label Phase II Study
Kong, Yuehong
Zhao, Xiangrong
Xu, Meiling
Pan, Jie
Ma, Yifu
Zou, Li
Peng, Qiliang
Zhang, Junjun
Su, Cunjin
Xu, Zhi
Zhou, Wei
Peng, Yong
Yang, Jiabao
Zhou, Chengliang
Li, Yujia
Guo, Qiuchen
Chen, Guangqiang
Wu, Hongya
Xing, Pengfei
Zhang, Liyuan
FRONTIERS IN IMMUNOLOGY, 2022, 13
[28] Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial
Reck, Martin
Schenker, Michael
Lee, Ki Hyeong
Provencio, Mariano
Nishio, Makoto
Lesniewski-Kmak, Krzysztof
Sangha, Randeep
Ahmed, Samreen
Raimbourg, Judith
Feeney, Kynan
Corre, Romain
Franke, Fabio Andre
Richardet, Eduardo
Penrod, John R.
Yuan, Yong
Nathan, Faith E.
Bhagavatheeswaran, Prabhu
DeRosa, Michael
Taylor, Fiona
Lawrance, Rachael
Brahmer, Julie
EUROPEAN JOURNAL OF CANCER, 2019, 116 : 137 - 147
[29] Efficacy and Safety of First-Line Cytokines versus Sunitinib and Second-Line Axitinib for Patients with Metastatic Renal Cell Carcinoma (ESCAPE Study): A Phase III, Randomized, Sequential Open-Label Study
Kadono, Yoshifumi
Konaka, Hiroyuki
Nohara, Takahiro
Izumi, Kouji
Anai, Satoshi
Fujimoto, Kiyohide
Koguchi, Tomoyuki
Ishibashi, Kei
Kawai, Noriyasu
Nakane, Keita
Iba, Akinori
Masumori, Naoya
Takahara, Shizuko
Mizokami, Atsushi
CANCERS, 2023, 15 (10)
[30] Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Weber, Jeffrey S.
D'Angelo, Sandra P.
Minor, David
Hodi, F. Stephen
Gutzmer, Ralf
Neyns, Bart
Hoeller, Christoph
Khushalani, Nikhil I.
Miller, Wilson H., Jr.
Lao, Christopher D.
Linette, Gerald P.
Thomas, Luc
Lorigan, Paul
Grossmann, Kenneth F.
Hassel, Jessica C.
Maio, Michele
Sznol, Mario
Ascierto, Paolo A.
Mohr, Peter
Chmielowski, Bartosz
Bryce, Alan
Svane, Inge M.
Grob, Jean-Jacques
Krackhardt, Angela M.
Horak, Christine
Lambert, Alexandre
Yang, Arvin S.
Larkin, James
LANCET ONCOLOGY, 2015, 16 (04) : 375 - 384

← 1 2 3 4 5 →